Vaccine List

Afluria is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine.

DAPTACEL is a vaccine indicated for active immunization against diphtheria, tetanus, and pertussis as a five-dose series in infants and children 6 weeks through 6 years of age (prior to 7th birthday)

FLUAD is a vaccine that helps protect against the flu. FLUAD is for people aged 65 years and older. Vaccination with FLUAD may not protect all people who receive the vaccine.

Flublok and Flublok Quadrivalent vaccines are given to people 18 years of age and older to help prevent influenza disease caused by influenza A virus subtypes and influenza type B virus contained in the vaccine. 

FLULAVAL QUADRIVALENT is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLULAVAL QUADRIVALENT is approved for use in persons aged 6 months and older.

FLUVIRIN® (Influenza Virus Vaccine) is an inactivated subunit influenza virus vaccine indicated for active immunization of persons aged 4 years and older against influenza disease caused by influenza virus subtypes A and B included in the vaccine.

Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, and Fluzone High-Dose vaccines are given to help prevent influenza disease caused by influenza A and B strains contained in each vaccine. Fluzone High-Dose vaccine is given to people 65 years of age and older.

Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, and Fluzone High-Dose vaccines are given to help prevent influenza disease caused by influenza A and B strains contained in each vaccine. Fluzone Quadrivalent vaccine is given to people 6 months of age and older.

GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) helps protect girls and women ages 9 to 26 against cervical, vaginal, vulvar, and anal cancers and genital warts caused by 9 types of HPV. GARDASIL 9 helps protect boys and men ages 9 to 26 against anal cancer and genital warts caused by those same HPV types. GARDASIL 9 may not fully protect everyone, nor will it protect against diseases caused by other HPV types or against diseases not caused by HPV. GARDASIL 9 does not prevent all types of cervical cancer, so it’s important for women to continue routine cervical cancer screenings. GARDASIL 9 does not treat cancer or genital warts. GARDASIL 9 is a shot that is usually given in the arm muscle. GARDASIL 9 may be given as 2 or 3 shots.

HAVRIX is a vaccine indicated for active immunization against disease caused by hepatitis A virus (HAV). HAVRIX is approved for use in persons 12 months of age and older. Primary immunization should be administered at least 2 weeks prior to expected exposure to HAV.

Imovax Rabies is a vaccine indicated for pre-exposure and post-exposure prophylaxis against rabies. Imovax Rabies vaccine is approved for use in all age groups.

A single dose of KINRIX is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and the fourth dose in the inactivated poliovirus vaccine (IPV) series in children 4 through 6 years of age whose previous DTaP vaccine doses have been with INFANRIX and/or PEDIARIX for the first three doses and INFANRIX for the fourth dose.

MENHIBRIX is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b. MENHIBRIX is approved for use in children 6 weeks of age through 18 months of age.

M-M-R ® II is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months of age or older.

PedvaxHIB is indicated for routine vaccination against invasive disease caused by Haemophilus influenzae type b in infants and children 2 to 71 months of age. PedvaxHIB should not be used in infants <6 weeks of age.

Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to H influenzae type b. Pentacel vaccine is approved for use as a 4-dose series in children 6 weeks through 4 years of age (prior to the fifth birthday).

Prevnar 13® is a vaccine indicated in children 6 weeks through 17 years (prior to the 18th birthday) for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and for children 6 weeks through 5 years of age (prior to the 6th birthday) for the prevention of otitis media caused by 7 of the 13 serotypes in the vaccine In adults 18 years of age and older, Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by S. pneumoniae serotypes in the vaccine Prevnar 13® does not protect against disease caused by S. pneumoniae serotypes that are not in the vaccine

Quadracel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis. A single dose of Quadracel vaccine is approved for use in children 4 through 6 years of age as a fifth dose in the diphtheria, tetanus, pertussis vaccination (DTaP) series, and as a fourth or fifth dose in the inactivated poliovirus vaccination (IPV) series, in children who have received 4 doses of Pentacel vaccine and/or DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed).

RECOMBIVAX HB is indicated for prevention of infection caused by all known subtypes of hepatitis B virus. RECOMBIVAX HB is approved for use in individuals of all ages. RECOMBIVAX HB Dialysis Formulation is approved for use in adult predialysis and dialysis patients 18 years of age and older.

RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.

Sanofi Pasteur confirms that YF-VAX® (Yellow Fever Vaccine) is unavailable to order in the U.S. until mid-2018 as the company transitions production to a new state-of-the-art facility, which is expected to occur in 2018. Sanofi Pasteur has worked with the FDA to make another yellow fever vaccine available in the US through an Expanded Access Investigational New Drug Application (IND). Manufactured by Sanofi Pasteur in France, this vaccine, STAMARIL® (Yellow Fever Vaccine [Live]), is registered and distributed in over 70 countries. However, it is considered investigational in the US, as it is not a US-licensed product. The Expanded Access Program has requirements similar to a clinical trial; thus Sanofi Pasteur can support only a limited number of sites. Working closely with the CDC, geographically distributed sites throughout the US were identified for inclusion in the program so patients can have continued access to yellow fever vaccine.

TRUVADA for PrEP (pre-exposure prophylaxis) is a prescription medicine that is used together with safer sex practices to help reduce the risk of getting HIV-1 through sex. This use is only for HIV-negative adults who are at high risk of getting HIV-1. To help determine your risk of getting HIV-1, talk openly with your healthcare provider about your sexual health.

TYPHIM Vi is manufactured by Sanofi Pasteur for intramuscular use for protection against Typhoid Fever. It is a sterile solution, prepared from the purified polysaccharide capsule of Salmonella typhi (Ty 2 strain). The purified polysaccharide capsule is diluted in isotonic buffer solution which contains phenol as preservative. The vaccine is a clear, colourless solution. Each single dose of 0.5 mL is formulated to contain 0.025 milligrams of purified capsular polysaccharide, preserved with phenol (less than 1.25 mg per dose). The isotonic buffer solution contains 4.15 mg of sodium chloride, 0.065 mg of sodium phosphate dibasic dihydrate and 0.023 mg of sodium phosphate monobasic.

VARIVAX is a vaccine indicated for active immunization for the prevention of varicella (ChickenPox) in individuals 12 months of age or older. Each dose is approximately 0.5 mL after reconstitution and is administered by subcutaneous injection.

Vaxchora is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1 in adults 18 through 64 years of age traveling to cholera-affected areas.

YF-VAX is indicated for active immunization for the prevention of yellow fever in persons 9 months of age and older in the following categories: Persons Living in or Traveling to Endemic Areas, Persons Travelling Internationally Through Countries with Yellow Fever, Laboratory Personnel